Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, End Point Status

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

The clinical trial report provides an overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

The report provides a snapshot of the global clinical trials landscapeReport provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point statusThe report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the companyThe report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishmentThe Report provides enrollment trends for the past five yearsReport provides latest news for the past three months

Reasons to Buy

Assists in formulating key business strategies with regards to investmentHelps in identifying prominent locations for conducting clinical trials which saves time and costProvides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunitiesSupports understanding of trials count and enrollment trends by country in global therapeutics marketAids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trialsFacilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

Report GuidanceThe analyst Clinical Trials Report CoverageClinical Trials by RegionClinical Trials and Average Enrollment by CountryTop Five Countries Contributing to Clinical Trials in Asia-PacificTop Five Countries Contributing to Clinical Trials in EuropeTop Countries Contributing to Clinical Trials in North AmericaTop Five Countries Contributing to Clinical Trials in Middle East and AfricaTop Five Countries Contributing to Clinical Trials in Central and South AmericaClinical Trials by G7 Countries: Proportion of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) to Gastrointestinal Clinical TrialsClinical Trials by Phase in G7 CountriesClinical Trials in G7 Countries by Trial StatusClinical Trials by E7 Countries: Proportion of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) to Gastrointestinal Clinical TrialsClinical Trials by Phase in E7 CountriesClinical Trials in E7 Countries by Trial StatusClinical Trials by PhaseIn Progress Trials by PhaseClinical Trials by Trial StatusClinical Trials by End Point StatusSubjects Recruited Over a Period of TimeClinical Trials by Sponsor TypeProminent SponsorsTop Companies Participating in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) Therapeutics Clinical TrialsProminent DrugsLatest Clinical Trials News on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)Sep 19, 2025: Skye Presents Phase 1B Data for Its Peripheral CB1-Inhibiting Antibody, Nimacimab, at EASDJul 09, 2025: Altimmune Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)Jun 27, 2025: PRD Therapeutics Announces Initiation of First-In-Human Study for PRD001Clinical Trial Profile SnapshotsAppendix

A selection of companies mentioned in this report includes, but is not limited to:

Pfizer IncAstraZeneca PlcThe Nucleus Network Pty LtdICON PlcEli Lilly and CoGalmed Pharmaceuticals LtdProSciento IncLabcorp Holdings IncNovartis AGThermo Fisher Scientific Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/3qnds8

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.